PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED (NCT06156215) | Clinical Trial Compass
CompletedNot Applicable
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
United States919 participantsStarted 2024-01-19
Plain-language summary
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are:
* does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit?
* does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit?
* considering recent national changes to funding and availability of updated vaccines, the investigators will examine the effects of these changes on vaccine acceptance and uptake in ED populations. Specifically, they will stratify EDs and ED patients according to the ED availability of vaccines, and they will also examine whether costs and availability of vaccines are a deterrent to patient acceptance and uptake of vaccines
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age \> 18 years
ā. Presenting to ED
ā. No receipt of COVID-19 booster within prior 6 months
ā. Able to provide informed consent
ā. Fluent in English or Spanish
ā. Anticipated ability to complete study intervention in ED i.e., able to watch a 3-minute videoclip
Exclusion criteria
ā. Major trauma such that it will preclude survey
ā. Inability to participate in a survey because of intoxication, altered mental status, or critical illness
ā. Incarceration
ā. Psychiatric hold
ā. Patients who state that they have already received a bivalent COVID-19 booster vaccine or other COVID-19 vaccine within the prior 6 months
What they're measuring
1
Number of Participants With 30-day Booster Vaccine Uptake